Short answer
CapsoVision, Inc (CV) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). ATM equity program authorizes up to $100 million in common-stock sales.
CapsoVision, Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- ATM equity program authorizes up to $100 million in common-stock sales
- No obligation to sell; management retains timing, volume and minimum-price control
- Potential shareholder dilution and selling pressure, depending on shares issued
- Cantor commission up to 3.0% of gross proceeds
- Form S-3 registration and prospectus supplement expected shortly
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 results announced August 13, 2026
- Financial details are contained in Exhibit 99.1, the furnished earnings press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $3.6M, up 10% year over year, driven by 13% more CapsoCam Plus capsules sold
- Gross margin declined to 51% from 55%, pressured by lower pricing, customs costs, and tariffs
- Operating expenses rose $3.0M to $9.5M, expanding net loss to $7.5M from $4.6M
- Cash declined to $9.1M at June 30 after $14.5M six-month operating cash burn
- Up to $100M at-the-market equity program creates funding capacity but potential shareholder dilution ahead of FDA and pipeline milestones
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CapsoVision, Inc 8-K filings
Get the next CV 8-K as it lands
Follow CV for push alerts, or ask the research agent what this filing means.